Surrozen, Inc./DE Accrued Liabilities, Current
Surrozen, Inc./DE (SRZN) had Accrued Liabilities, Current of $5.95 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $5.95M.
- 2026-03-31: Accrued Liabilities, Current $6.75M.
- 2025-12-31: Accrued Liabilities, Current $7.91M.
- 2025-09-30: Accrued Liabilities, Current $4.75M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $5.95M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $6.75M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $7.91M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $4.75M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $4.19M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $9.09M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $5.18M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $4.32M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $3.64M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $3.48M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $4.13M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $3.95M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $3.90M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $5.32M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $6.85M 10-K · filed 2024-04-10 | |
| 2022-09-30 | $6.13M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $6.01M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $4.93M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $8.66M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $8.49M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $1.54M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $986.59K 10-Q · filed 2021-05-24 | |
| 2020-12-31 | $3.39M 10-K · filed 2022-03-28 | $290.15K 10-Q · filed 2021-05-24 |
| 2020-09-30 | $30.00K 10-Q/A · filed 2021-01-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |